Bioscience

C-Path secures $11.8M grant from Gates Foundation to help tuberculosis drug development

February 13, 2014

By Flinn Foundation

The Tucson-based Critical Path Institute has received a three-year, $11.8 million grant from the Bill & Melinda Gates Foundation to develop models that will optimize the design of clinical trials and address challenges associated with the development of effective treatments for tuberculosis.

The Critical Path to TB Drug Regimens Initiative (CPTR), which was co-founded by C-Path, the Gates Foundation, and the Global Alliance for TB Drug Development, seeks to advance the science behind tuberculosis drug treatments and work to develop and test promising drug combinations to create new multi-drug treatments.

In support of the project, Janssen Research & Development, a subsidiary of Johnson & Johnson, will provide data from its clinical trials of Sirturo, a new tuberculosis drug approved for use in December 2012, C-Path said.

For more information:

“Gates Foundation delivers an $11.8M grant to fuel tuberculosis R&D,” FierceBiotechResearch, 2/7/14

“C-Path gets $11.8M grant to help TB drug development,” Arizona Daily Star, 2/4/14

“Critical Path Institute receives grant to accelerate development of tuberculosis treatments,” Critical Path Institute, 2/4/14